
Editorial
Select search scope: search across all journals or within the current journal

In conjunction with a community partnership with the American Lung Association, the Broome County Health Department, the Asthma Coalition of the Southern Tier, and the Decker School of Nursing, the American Lung Association’s
Biomarkers, or “markers,” are used to measure an aspect of the biology or physiology of health and clinical disease. In the case of asthma, the most desirable biomarkers measure airflow obstruction caused by inflammation. Although many biomarkers have been proposed to assist in the diagnosis of asthma and to indicate the degree of disease severity or responsiveness to treatment, few are noninvasive, inexpensive, or measure clinically important aspects of disease activity. Currently, spirometry is the only established biomarker used to confirm the diagnosis and determine lung health. However, the National Heart Lung and Blood Institute’s Expert Panel characterizes other biomarkers of particular interest in asthma. This review will compare and contrast spirometry (something old) with one of the newly proposed biomarkers–fractional exhaled nitric acid (something new)–with respect to what aspects of asthma they propose to measure, what they do measure, and what sources of systematic and random error arise in the measurement of these variables.
Spirometry is a valuable tool for diagnosing asthma, establishing the severity, and assessing the control of asthma over time in those patients who can perform the procedure. Response to bronchodilator also helps in diagnosing the disease and assessing control. Guidelines and standards are available to help perform and interpret spirometry and response to bronchodilator tests. These guidelines come from the American Thoracic Society, the European Respiratory Society, the National Asthma Education and Prevention Program—Expert Panel Report-3, and the American Association for Respiratory Care Clinical Practice Guidelines. The objective measurements, especially in the forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and the FEV1/FVC, enable proper management and provide continuing assessment to check the effectiveness of therapy and to follow the disease over time.




